Moleculin Biotech, Inc 8-K, filed Feb 3, 2023
Moleculin Biotech, Inc. (MBRX)
8-K
2023-02-03
For: 2023-02-03
View Original
Added on
April 06, 2026
About this 8-K
Moleculin Biotech, Inc filed this 8-K on February 3, 2023.
Items reported
- Item 1.02: Ended a material agreement
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): February 3, 2023
(Exact Name of Registrant as Specified in its Charter)
|
|
|
|
|
(State or Other Jurisdiction of Incorporation or Organization)
|
(Commission File No.)
|
(I.R.S. Employer Identification No.)
|
(Address of principal executive offices and zip code)
(713 ) 300-5160
(Registrant’s telephone number, including area code)
(Former name or former address, if changed from last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
|
|
|
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol (s)
|
Name of each exchange on which registered
|
|
|
|
The
|
Item 1.02 Termination of a Material Definitive Agreement.
On February 3, 2023, Moleculin Biotech, Inc. (“Company”) delivered written notice to Oppenheimer & Co. Inc. (the “Agent”) that it was terminating its At Market Issuance Sales Agreement, dated June 25, 2021 (the “ATM Agreement”), pursuant to Section 13(b) of the ATM Agreement, effective on February 13, 2023. Pursuant to the ATM Agreement, the Company could offer and sell, from time to time, through the Agent, shares of the Company’s common stock having an aggregate offering price of up to $50,000,000. During the term of the ATM Agreement, the Company did not sell any shares of its common stock thereunder. The ATM Agreement was terminable at will by the Company with no penalty.
A copy of the ATM Agreement was filed as Exhibit 1.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 25, 2021 (the “Prior Form 8-K”). The description of the ATM Agreement contained herein does not purport to be complete and is qualified in its entirety by reference to the copy of the Sales Agreement filed as Exhibit 1.1 to the Prior Form 8-K.
SIGNATURE
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
MOLECULIN BIOTECH, INC.
|
||||
|
Date: February 3, 2023
|
||||
|
|
By: |
/s/ Jonathan P. Foster
|
||
|
Jonathan P. Foster
|
||||
|
Chief Financial Officer
|
||||
2